A number of reports have shown that PRL is an immune-stimulating hormone that is capable of stimulating organ-specific inflammatory disease in humans. More recently, hyperprolactinemia has been associated with the active phase of the immune-complex-mediated autoimmune disease, systemic lupus erythematosus. The theory that PRL contributes substantially to disease activity was upheld in the NZB/W mouse model of spontaneous, hormone-sensitive lupus. Implanted pituitary glands resulted in hyperprolactinemia, accelerated proteinuria, high levels of circulating IgG, and premature death. Therapeutic studies with NZB/W mice, as well as anecdotal evidence from a small number of patients, have provided evidence that PRL suppressive therapy may be beneficial in selected cases of autoimmune disease.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/1043-2760(93)90103-l | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
State of knowledge of the relationship between celiac disease and oral pathology: A scoping review.
Med Oral Patol Oral Cir Bucal
January 2025
Oral Medicine, Department of Stomatology School of Dentistry, University of Granada Granada, Paseo de Cartuja s/n, 18071 Granada, Spain
Background: Celiac disease (CD) is a systemic disorder characterized by an enteropathy of highly variable clinical expression, in which the relationship with oral pathology has not yet been fully elucidated. We aimed to update the current knowledge on oral manifestations in CD, to identify evidence gaps and to point out future research lines.
Material And Methods: PRISMA-ScR guidelines were followed.
Oral health-related quality of life in primary Sjögren's Syndrome.
Med Oral Patol Oral Cir Bucal
January 2025
465 Jose Marmol St, Zip Code 1236 Buenos Aires City, Argentina
Background: Primary Sjögren Syndrome (pSS) is an autoimmune disease that usually affects salivary glands. Research about the impact of oral health in quality of life of patients with pSS is scarce.
Objectives: to describe the characteristics of oral involvement in patients with pSS; To assess quality of life related to oral health (QOL-OH); to determine association between QOL-OH and saliva production, disease activity, and damage.
ISCT MSC committee statement on the US FDA approval of allogenic bone-marrow mesenchymal stromal cells.
Cytotherapy
January 2025
Osteoarthritis Research Program, Division of Orthopedic Surgery, Schroeder Arthritis Institute, University Health Network, Toronto, Ontario, Canada; Krembil Research Institute, University Health Network, Toronto, Ontario, Canada; Institute of Biomedical Engineering, University of Toronto, Toronto, Ontario, Canada; Department of Medicine, Division of Hematology, University of Toronto, Toronto, Ontario, Canada. Electronic address:
The December 2024 US Food and Drug Administration (FDA) approval of Mesoblast's Ryoncil (remestemcel-L-rknd)-allogeneic bone marrow mesenchymal stromal cell (MSC(M)) therapy-in pediatric acute steroid-refractory graft-versus-host-disease finally ended a long-lasting drought on approved MSC clinical products in the United States. While other jurisdictions-including Europe, Japan, India, and South Korea-have marketed autologous or allogeneic MSC products, the United States has lagged in its approval. The sponsor's significant efforts and investments, working closely with the FDA addressing concerns regarding clinical efficacy and consistent MSC potency through an iterative process that spanned several years, was rewarded with this landmark approval.
View Article and Find Full Text PDFEngineering Resilient CAR T Cells for Immunosuppressive Environment.
Mol Ther
January 2025
Brown Center for Immunotherapy. Indiana University School of Medicine. 975 W. Walnut St., IB554A, Indianapolis, IN 46202. Electronic address:
Chimeric Antigen Receptor (CAR) T cell therapy has revolutionized cancer treatment and is now being explored for other diseases, such as autoimmune disorders. While the tumor microenvironment (TME) in cancer is often immunosuppressive, in autoimmune diseases, the environment is typically inflammatory. Both environments can negatively impact CAR T cell survival: the former through direct suppression, hypoxia, and nutrient deprivation, and the latter through chronic T cell receptor (TCR) engagement, risking exhaustion.
View Article and Find Full Text PDFImpact of Periodontal Treatment on Early Rheumatoid Arthritis and the Role of Porphyromonas gingivalis Antibody Titers.
Med Sci Monit
January 2025
Department of Internal Medicine IV, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, Japan.
BACKGROUND Periodontal disease and rheumatoid arthritis (RA) are closely related, and periodontal therapy can potentially improve RA activity. However, it is not clear in which RA patient populations are more effective periodontal therapy for RA treatment. This study aimed to evaluate the effects of treatment for periodontal disease in 30 patients with rheumatoid arthritis and the titers of antibodies to Porphyromonas gingivalis (P.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!